Tiziana Life Sciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Ivor Elrifi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.1yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
CEO
Ivor Elrifi
less than a year
Tenure
Dr. Ivor R. Elrifi, Ph D., is Chief Executive Officer of Tiziana Life Sciences Ltd from August 19, 2024 and its Executive Director from 2024. Dr. Elrifi is a Member at Mintz, Levin, Cohn, Ferris, Glovsky a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 10.7yrs | US$817.00k | 36.06% € 29.3m | |
| CEO & Executive Director | less than a year | no data | no data | |
| COO & CFO | less than a year | no data | no data | |
| Chief Development Officer | 1.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.6yrs | no data | no data |
1.1yrs
Average Tenure
52yo
Average Age
Experienced Management: 0RP's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 10.7yrs | US$817.00k | 36.06% € 29.3m | |
| CEO & Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 4.4yrs | US$89.00k | no data | |
| Chairman of Scientific Advisory Board | 8.9yrs | no data | no data | |
| Independent Non-Executive Director | 9.1yrs | US$89.00k | 0.0076% € 6.1k | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.9yrs | no data | no data |
8.9yrs
Average Tenure
73yo
Average Age
Experienced Board: 0RP's board of directors are considered experienced (8.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:15 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tiziana Life Sciences Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Robin Campbell | Equity Development Limited |
| Raghuram Selvaraju | H.C. Wainwright & Co. |